Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays

Background: The recent elucidation of the importance of serological free pr ostate-specific antigen (PSA) in the diagnosis of prostate cancer has creat ed a demand for immunoassays specific for free PSA. Methods: We developed and characterized 11 monoclonal antibodies with high affinities for PSA (K-a values from 1.1 x 10(8) to 1.8 x 10(10) L/mol), onl y 3 of which cross-react with human glandular kallikrein (hK2). Using these antibodies and PSA antibodies developed by others, in conjunction with tim e-resolved fluorometry, we developed ultrasensitive sandwich immunoassays s pecific for the free form of PSA. Results: The analytical detection limit of these immunoassays is 0.001 mu g /L. To our knowledge, this is the most sensitive free PSA assay reported to date. The free PSA immunoassays exhibit <1% cross-reactivity with PSA-alph a(1)-antichymotrypsin, show no cross-reactivity with hK2, and correlate wel l with established free PSA kits. The 11 antibodies developed by our group, in conjunction with 4 commercially available antibodies, were used to gene rate a putative epitope map of the PSA molecule. Conclusion: The highly sensitive free PSA immunoassays may be used for meas uring PSA subfractions in female serum, an application currently impossible with other reported free PSA immunoassays. (C) 1999 American Association f or Clinical Chemistry.